Mab-CR3022-ScFv- 1.0 mg

85,00 excl. Vat

Categories: ,

X-MAB-0001 – Mab-CR3022-ScFv
ALIQUOTING: 1 X 1.0 mg vial
STORAGE: < -18 °C

The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV-1 Spike protein as well as SARS-CoV-2 Spike protein. Structural modelling showed that the antibody is specific for a cryptic epitope that is only revealed when at least two of the three spike proteins in the native trimeric state are in a conformation competent to bind the receptor. (Yuan et al. 2020). Recombinant Mab-CR3022- ScFv is a recombinant single chain ScFV version of CR3022 for research use only. CR3022 is also available as a chimeric human ScFv- IgG-CH3, ScFv- IgM-CH3, ScFv-IgA-CH3 modubody, pure ScFv and biotinylated ScFv antibody fragment. For convenient amino-based conjugation, the product is free from amino-based puffers.

This product is for LABORATORY RESEARCH USE ONLY, not for diagnostic, therapeutic, drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

For shipping at ambient temperature the protein is liquid-stabilized with a HEPES, NaCl, small molecule buffer base at neutral pH.

Stock solutions can be diluted in appropriate buffers.

For long term storage the liquid-stabilized protein should be stored below – 18 °C. Repeated freeze-thaw cycles (> 5) should be avoided. For long term usage, stock solutions can be frozen in working aliquots.

The E. coli expressed recombinant CR3022-ScFv has a molecular mass of 30 kDa and a predicted isoelectric point of 8.8.

For protein conjugation a final concentration of 0.2 to 1 mg/ml is recommended. For direct microplate coating a final concentration of 0.5 to 5 μg/ml is recommended. For optimal performance the reagent should be titrated for each application.

1. Yuan M. et al., A highly conserved cryptic
epitope in the receptor binding domains of
SARS-CoV-2 and SARS-CoV,
Science. 368: 630-633 (2020).

2. Meulen J., et al. Human Monoclonal
Antibody Combination against SARS
Coronavirus: Synergy and Coverage of Escape Mutants,
PlosMed., (2006).


BioThinx warrants, that at the time of the quality release or subsequent retest date this product conformed to the information contained in this publication. Purchaser must determine the suitability of the product(s) for its particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip. No other warranties, express or implied, are granted, including without limitation, implied warranties of merchantability, fitness for any particular purpose, or non-infringement